We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Time-Release Microcapsules Deliver Anti-Inflammatory Hormone to Repair Cartilage Damaged by Osteoarthritis

By LabMedica International staff writers
Posted on 03 Feb 2015
Microcapsules loaded with C-type natriuretic peptide (CNP) have been shown to reduce the type of inflammation characteristic of osteoarthritis (OA) in a model system based on the culture of animal cartilage tissue.

CNP is processed proteolytically to form a secreted hormone of the natriuretic peptide family. More...
The hormone regulates the growth and differentiation of cartilaginous growth plate chondrocytes and may also be vasoactive (causing constriction or dilation of blood vessels) and natriuretic (inhibiting reabsorption of cations, particularly sodium, from urine). Chondrocytes have the potential to repair cartilage damage observed in (OA), but developing treatments for OA based on CPN has been challenging due to poor targeting and difficulty in delivery of the hormone, which readily breaks down in vivo.

To overcome the problems of targeting and delivery, investigators at Queen Mary University of London (United Kingdom) prepared polyelectrolyte microcapsules loaded with CNP and examined whether a layer-by-layer (LbL) approach could have protective effects in cartilage explants treated with the pro-inflammatory cytokine, interleukin-1beta (IL-1beta). The two-micrometer in diameter microcapsules comprised individual CNP-containing layers that released the hormone slowly over time.

Results published in the January 4, 2015, online edition of the journal Biomacromolecules revealed that images obtained by SEM (scanning electron microscopy) showed uniform, spherical microcapsules two to three micrometers in diameter with morphological characteristic similar to templates loaded with or without CNP. The protein was localized around the external surface of the microcapsules with encapsulation efficiencies more than 82.9%. CNP release profiles were broadly similar following nine days of culture. The presence of CNP microcapsules did not significantly affect cell viability (80%) with DNA values that remained stable throughout the culture conditions. Treatment of cartilage explants with CNP microcapsules led to concentration-dependent inhibition of nitric oxide (NO) release in response to IL-1beta and restoration of matrix synthesis.

The results demonstrated the potential for controlled delivery of CNP to dampen pro-inflammatory effects induced by IL-1beta in cartilage explants and to promote cartilage repair in vivo.

Senior author Dr. Tina Chowdhury, associate professor of bioengineering at Queen Mary University of London, said, "If this method can be transferred to patients it could drastically slow the progression of osteoarthritis and even begin to repair damaged tissue. CNP is currently available to treat other conditions such as skeletal diseases and cardiovascular repair. If we could design simple injections using the microcapsules, this means the technology has the potential to be an effective and relatively cheap treatment that could be delivered in the clinic or at home."

Related Links:

Queen Mary University of London



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.